PMID- 11766830
OWN - NLM
STAT- MEDLINE
DCOM- 20020313
LR  - 20190921
IS  - 0886-0440 (Print)
IS  - 0886-0440 (Linking)
VI  - 16
IP  - 2
DP  - 2001 Mar-Apr
TI  - Growth hormone treatment in dilated cardiomyopathy.
PG  - 127-31
AB  - Treatment with human recombinant growth hormone (GH) has yielded conflicting 
      results in patients with congestive heart failure. We analyzed the baseline 
      somatotrophic axis in 50 patients with dilated cardiomyopathy. Then, a 
      double-blind, randomized, placebo-controlled study of GH was performed. We 
      randomly allocated these patients to treatment with subcutaneous GH (2 IU daily) 
      or placebo for a minimum of 12 weeks. The primary end-points were the effect on 
      left ventricular (LV) mass and systolic wall stress. The secondary endpoint was 
      LV ejection fraction. Severity of heart failure as determined by cardiac index, 
      LV end-diastolic diameter, and plasma noradrenaline concentrations correlated 
      markedly with baseline serum insulin-like growth factor-1 (IGF-1) levels. 
      Patients in the GH group had an increase in LV mass compared with the placebo 
      group (p = 0.0001). There was no significant difference in LV systolic wall 
      stress, mean blood pressure, or systemic vascular resistance between the two 
      groups. New York Heart Association (NYHA) functional classification and distance 
      in 6-minute walk test remained unchanged. The change in IGF-1 concentrations 
      between GH and placebo group was notably related (p = 0.0001) to the change in LV 
      mass (p = 0.0001). The GH-induced increase of IGF-1 predicted the changes of 
      ejection fraction (p < 0.05). A marked increase of ejection fraction of 7% was 
      observed in patients whose IGF-1 increased by more than the median increase, in 
      comparison to the patients with an increase below the median (p = 0.03). Serum 
      levels of IGF-1 reflecting GH secretion are diminished in relation to severity of 
      heart failure in patients with dilated cardiomyopathy. GH-induced increases of 
      IGF-1 of more than 80 pg/mL caused notable improvement of ejection fraction. 
      There is a marked increase in LV mass in patients with dilated cardiomyopathy 
      given GH. Changes in LV mass are related to changes in serum IGF-1 
      concentrations.
FAU - Perrot, A
AU  - Perrot A
AD  - Charitz/Franz-Volhard-Klinik am Max Delbruck Centrum fur Molekulare Medizin, 
      Humboldt Universitat zu Berlin, Germany. perrot@fvk-berlin.de
FAU - Ranke, M B
AU  - Ranke MB
FAU - Dietz, R
AU  - Dietz R
FAU - Osterziel, K J
AU  - Osterziel KJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Card Surg
JT  - Journal of cardiac surgery
JID - 8908809
RN  - 0 (Biomarkers)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Dilated/blood/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Growth Hormone/*therapeutic use
MH  - Heart Ventricles/drug effects
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Regression Analysis
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2002/01/05 10:00
MHDA- 2002/03/14 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/03/14 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 10.1111/j.1540-8191.2001.tb00497.x [doi]
PST - ppublish
SO  - J Card Surg. 2001 Mar-Apr;16(2):127-31. doi: 10.1111/j.1540-8191.2001.tb00497.x.